Baxter: The Chart Is Turning Before the BusinessBaxter International Inc.BATS:BAXstouflacrucoBaxter International (BAX) has fallen almost 74% from its 2021 peak, turning a former healthcare stalwart into a complex turnaround situation. The latest rebound is significant: the stock has recovered from approximately $17 to nearly $25, while momentum is turning upward from deeply oversold levels. However, my Master Buy Scanner V2 is making an important distinction: This is not yet a BUY. It is a GROWTH WATCH. THE SIGNAL The monthly and two-month views show improving technical conditions: • Scanner score: 3/3 • Decision: GROWTH WATCH • Action: WATCH • Entry quality: 60–75% • Technical cycle: ACTIVE • Momentum cross: YES • Recovery: CONFIRMED • Volume: ACCUMULATION • Model position size: NONE — 0% The two-month setup is stronger, with seven of ten technical conditions positive. But there is still no formal buy event. Why? Because the chart may be turning before Baxter’s fundamentals have stabilized. WHAT HAPPENED TO BAXTER? Baxter sells essential hospital products, infusion systems, connected-care equipment and injectable pharmaceuticals. Demand for these products is durable, but the company has suffered from operational problems, weak margins, high debt and portfolio disruption. Baxter completed the sale of its Vantive Kidney Care business in January 2025 after agreeing a $3.8 billion transaction with Carlyle. The original estimate was approximately $3 billion in net after-tax proceeds. The sale simplified the company and provided capital for debt reduction—but it did not immediately repair the remaining operations. (https://investor.baxter.com/investors/events-and-news/news/press-release-details/2024/Baxter-Announces-Definitive-Agreement-to-Divest-Its-Vantive-Kidney-Care-Segment-to-Carlyle-for-3.8-Billion/default.aspx) First-quarter 2026 results show why the scanner remains cautious: • Continuing-operations sales: $2.7 billion, up 3% reported • Organic sales: down 1% • U.S. organic sales: down 4% • GAAP EPS: negative $0.03 • Adjusted EPS: $0.36, down 35% Performance was affected by tariffs, higher manufacturing costs and reduced infusion-pump sales following the shipment and installation hold on the Novum IQ large-volume pump. Healthcare Systems & Technologies also reported a 2% organic decline. The brighter spot was Pharmaceuticals, where reported sales increased 7% and organic sales grew 1%. (https://investor.baxter.com/investors/events-and-news/news/press-release-details/2026/Baxter-Reports-First-Quarter-2026-Results/default.aspx) Cash generation also improved. Free cash flow from continuing operations reached $76 million, compared with negative $221 million one year earlier. That is progress—but not yet proof of a durable turnaround. QUALITY AND VALUATION The scanner’s fundamental picture is mixed. Business quality is ORANGE: • Quality score: 1.5/3 • Return on capital: -5.39% • Margin trend: -0.30% • Current profitability: RED • Cash generation: positive but modest Valuation and debt are also ORANGE: • Value score: 2.5/6 • Cash yield: 5.67% • Business-price multiple: 10.1x • Cash-flow multiple: 49.08x • Debt-to-equity: 1.60 • Debt: approximately $9.7 billion The business-price multiple looks attractive, but the cash-flow multiple and negative reported earnings tell a different story. Baxter may appear inexpensive relative to sales or normalized earnings, but it is not obviously cheap relative to current profitability. The dividend is no longer a meaningful part of the thesis either. Baxter’s indicated annual dividend rate is now only $0.04 per share. (https://investor.baxter.com/investors/resources-and-faqs/dividend-and-stock-split-information/default.aspx) This is a turnaround and deleveraging thesis—not an income investment. THE GROWTH QUESTION The scanner gives Baxter only 1/2 for growth: • Three-year sales growth: -8.14% • Future profit-growth estimate: unavailable • Estimate trend: stable • Growth outlook: ORANGE Calling this a GROWTH WATCH does not mean Baxter is currently growing strongly. It means depressed earnings could eventually recover if management can stabilize sales, improve manufacturing efficiency, resolve the infusion-pump disruption and reduce financial pressure. Management has reiterated a 2026 outlook of approximately flat organic sales and adjusted EPS of $1.85–$2.05. That guidance suggests stabilization—not rapid growth. (https://investor.baxter.com/investors/events-and-news/news/press-release-details/2026/Baxter-Reports-First-Quarter-2026-Results/default.aspx) THE TECHNICAL SETUP Technically, the first stage of a possible bottom is developing. Key levels I am watching: • $20–21: immediate pivot and support • $17–18: structural low and invalidation zone • Around $25: first resistance • $28–30: more meaningful confirmation • $34–36: next recovery zone The momentum cross and accumulation signal are encouraging, but the base remains wide and immature. A sustained move above $25 would be constructive. A recovery above $28–30 would provide stronger evidence that the long-term downtrend is changing. Conversely, losing $20 would weaken the setup. A break below $17 would invalidate the emerging bottoming thesis. THE BULL CASE • Essential healthcare products with recurring demand • Portfolio simplified after the Vantive sale • Improving free cash flow • Strong Pharmaceuticals performance • Management focused on operational improvement • Deep 74% drawdown • Momentum turning from oversold conditions • Recovery and accumulation signals confirmed THE BEAR CASE • Organic sales remain negative • Return on capital is below zero • Adjusted EPS fell 35% in Q1 • Novum IQ disruption remains unresolved • Manufacturing and tariff pressure • High debt burden • Weak current cash-flow valuation • No formal scanner buy event • The rebound could fail below major resistance MY CURRENT FRAMEWORK I would treat Baxter as a watchlist turnaround—not a confirmed investment. My framework would be: • Wait for the price to hold above $20–21 • Look for confirmation through $25 and preferably $28–30 • Require improving organic sales and margins • Monitor free cash flow and debt reduction • Reassess the thesis below $17–18 Baxter is scheduled to report second-quarter results on July 30, making organic growth, Novum IQ progress, margins and cash generation the immediate tests of the recovery thesis. (https://investor.baxter.com/investors/events-and-news/events/event-details/2026/Baxter-Second-Quarter-2026-Financial-Results/default.aspx) TRY THE SCANNER Master Buy Scanner V2 distinguishes between a confirmed BUY and an improving stock that still needs proof. That is exactly what GROWTH WATCH means here: the ingredients for a recovery are appearing, but the evidence is not yet strong enough to justify a position. Add the scanner to your TradingView charts: THE QUESTION What would make you consider Baxter? A — Confirmation above $25 B — Improving organic sales and margins C — More debt reduction D — Avoid until the Novum IQ issue is resolved Comment A, B, C or D—and share your Baxter thesis. This is not financial advice. Always conduct your own research and manage risk according to your investment horizon.